Literature DB >> 29063114

[Research progress of complement-C1q/tumor necrosis factor-related protein 3].

Cheng-Lin Zhang1, Li-Ling Wu2, Li Li3.   

Abstract

Complement-C1q/tumor necrosis factor-related protein 3 (CTRP3) is an adipokine that primarily identified in 2003 and is an important member of CTRP family. CTRP3 is expressed in various tissues and cell types, and is highly conserved among different species. Multiple novel functions of CTRP3 have been reported recently as the further research on this protein develops. CTRP3 not only affects the proliferation of chondrocytes and the pathogenesis of osteoarthritis, but also regulates multiple physiological and pathological processes including the secretion of testosterone and adipokines, glucose and lipid metabolism, mitochondrial biogenesis, inflammatory response, cell apoptosis, angiogenesis, vascular calcification and ventricular remodeling. The present review mainly focuses on the research progresses on CTRP3, including its discovery, gene and protein structure, expression regulation, and biological functions. The progresses summarized may provide new clues for the further investigation of CTRP3.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29063114

Source DB:  PubMed          Journal:  Sheng Li Xue Bao        ISSN: 0371-0874


  2 in total

1.  C1q/tumor necrosis factor-related protein-3 (CTRP3) activated by forkhead box O4 (FOXO4) down-regulation protects retinal pericytes against high glucose-induced oxidative damage through nuclear factor erythroid 2-related factor 2 (Nrf2)/Nuclear factor-kappaB (NF-κB) signaling.

Authors:  XiuYa Zeng; YouYuan Peng; YanFeng Wang; KeMing Kang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

2.  Implications of C1q/TNF-related protein superfamily in patients with coronary artery disease.

Authors:  Yanwei Zhang; Caihong Liu; Jing Liu; Rui Guo; Zheyi Yan; Wenxia Liu; Wayne Bond Lau; Xiangying Jiao; Jimin Cao; Kun Xu; Yongping Jia; Xinliang Ma; Yajing Wang
Journal:  Sci Rep       Date:  2020-01-21       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.